Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | STK4 | Q13043 | 1/20 | 0.45 |
| ▸ | STK3 | Q13188 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030758 | 0.81 | CNR2 (0.49) | KDRFGFR3CNR2FYN | |
| SCHEMBL13336658 | 0.80 | KDR (0.69) | KDRFGFR3 | |
| SCHEMBL3025511 | 0.79 | CNR2 (0.49) | KDRFGFR3CNR2FYN | |
| SCHEMBL3031389 | 0.78 | FYN (0.71) | KDRFGFR3FYNPIK3CDPIK3R1 | |
| Formic Acid SCHEMBL3325341 | 0.78 | KDR (0.66) | KDRFGFR3 | |
| SCHEMBL3026704 | 0.77 | KDR (0.65) | KDRFGFR3FYNPIK3CDPIK3R1 | |
| Hydrochloric Acid SCHEMBL20293639 | 0.76 | HDAC2 (0.55) | — | |
| SCHEMBL3326922 | 0.76 | FGFR3 (0.57) | KDRFGFR3FYN | |
| SCHEMBL3325347 | 0.75 | KDR (0.55) | KDRFGFR3 | |
| SCHEMBL3326947 | 0.75 | KDR (0.52) | KDRFGFR3AOC3LRRK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | claimed |
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-2212323-A2 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | KDR 372/4885FGFR3 32/4885CNR2 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.